1. Search Result
Search Result
Results for "

NMDA

" in MCE Product Catalog:

120

Inhibitors & Agonists

1

Screening Libraries

5

Peptides

26

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-17551
    NMDA

    N-Methyl-D-aspartic acid

    iGluR Endogenous Metabolite Neurological Disease
    NMDA is a specific agonist for NMDA receptor mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor.
  • HY-12962
    NMDA-IN-1

    iGluR Neurological Disease
    NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.
  • HY-136459
    NMDA receptor antagonist 2

    iGluR Neurological Disease
    NMDA receptor antagonist 2 is a potent and orally active NR2B subtype-selective NMDA antagonist with an IC50 and a Ki of 1.0 nM and 0.88 nM, respectively. NMDA receptor antagonist 2 is used for the study of neuropathic pain and Parkinson’s disease.
  • HY-30006
    1-Aminocyclobutanecarboxylic acid

    iGluR Neurological Disease
    1-Aminocyclobutanecarboxylic acid is a NMDA receptor partial agonist acting at the glycine site, NR1.
  • HY-107695
    Remacemide hydrochloride

    FPL 12924AA

    iGluR Sodium Channel Neurological Disease
    Remacemide hydrochloride (FPL 12924AA), a moderate inhibitor of the Na + channel, is a weak uncompetitive NMDA receptor antagonist with IC50s of 68 μM and 76 μM for MK-801 binding and NMDA currents, respectively. Remacemide hydrochloride is an anticonvulsant agent.
  • HY-P1293
    Conantokin G

    iGluR Neurological Disease
    Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC50 of 480 nM. Conantokin G has neuroprotective properties.
  • HY-P1293A
    Conantokin G TFA

    iGluR Neurological Disease
    Conantokin G TFA, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G TFA inhibits NMDA-evoked currents in murine cortical neurons with an IC50 of 480 nM. Conantokin G TFA has neuroprotective properties.
  • HY-108235
    Lanicemine

    AZD6765

    iGluR Neurological Disease
    Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects.
  • HY-108235A
    Lanicemine dihydrochloride

    AZD6765 dihydrochloride; ARL 15896AR

    iGluR Neurological Disease
    Lanicemine (AZD6765) dihydrochloride is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects.
  • HY-106408A
    Nelonemdaz potassium

    Salfaprodil; Neu2000 potassium

    iGluR Neurological Disease
    Nelonemdaz (Salfaprodil) potassium is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz potassium is also a free radical scavenger. Nelonemdaz potassium has excellent neuroprotection against NMDA- and free radical-induced cell death.
  • HY-106408
    Nelonemdaz

    Salfaprodil free base; Neu2000

    iGluR Neurological Disease
    Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death.
  • HY-108235B
    (Rac)-Lanicemine

    (Rac)-AZD6765

    iGluR Neurological Disease
    (Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects.
  • HY-100822A
    (S)-(-)-HA 966

    (-)-HA 966

    iGluR Neurological Disease
    (S)-(-)-HA 966 ((-)-HA 966), a γ-Hydroxybutyrate-like agent, is weakly active as an NMDA-receptor antagonist. (S)-(-)-HA 966 possesses muscle relaxant action and prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear.
  • HY-101178
    L-689560

    iGluR Neurological Disease
    L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases.
  • HY-121488
    GP130 receptor agonist-1

    Interleukin Related Neurological Disease
    GP130 receptor agonist-1 is a potent, brain-penetrant and orally active GP130 receptor agonist. GP130 receptor agonist-1 has a neuroprotective effect on NMDA-induced neurotoxicity.
  • HY-101372A
    Oxotremorine M iodide

    mAChR Neurological Disease
    Oxotremorine M iodide is a potent and non-selective muscarinic acetylcholine receptor (mAChR) agonist. Oxotremorine M iodide potentiates NMDA receptors by muscarinic receptor dependent and independent mechanisms.
  • HY-15084A
    (-)-Dizocilpine maleate

    (-)-MK-801 maleate

    iGluR Neurological Disease
    (-)-Dizocilpine maleate ((-)-MK-801 maleate) is a less active (-)-enantiomer of Dizocilpine. (-)-Dizocilpine maleate is a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with a Ki of 211.7 nM. (-)-Dizocilpine maleate has antidepressant effects.
  • HY-B0030
    D-Cycloserine

    iGluR Bacterial Antibiotic Infection Neurological Disease
    D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research.
  • HY-12323
    ISX-9

    Isoxazole 9

    Calcium Channel Neurological Disease
    ISX-9 (Isoxazole 9) is a potent inducer of adult neural stem cell differentiation. ISX-9 activates Ca 2+ influx through both voltage-gated Ca 2+ channels and NMDA receptors and increases neuroD expression. ISX-9 also induces cardiomyogenic differentiation of Notch-activated epicardium-derived cells (NECs).
  • HY-100815B
    (RS)-AMPA

    (±)-AMPA

    iGluR Neurological Disease
    (RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors.
  • HY-100815D
    (RS)-AMPA monohydrate

    (±)-AMPA monohydrate

    iGluR Neurological Disease
    (RS)-AMPA ((±)-AMPA) monohydrate is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA monohydrate does not interfere with binding sites for kainic acid or NMDA receptors.
  • HY-106467B
    Caroverine hydrochloride

    iGluR Neurological Disease
    Caroverine hydrochloride is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine hydrochloride is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine hydrochloride can be used for the research of inner ear tinnitus.
  • HY-19434A
    cis-ACPD

    iGluR mGluR Neurological Disease
    cis-ACPD is a potent agonist of NMDA receptor, with an IC50 of 3.3 μM. cis-ACPD is also a selective agonist of group II mGluR, with EC50s of 13 μM and 50 μM for mGluR2 and mGluR4, respectively.
  • HY-109097
    Otaplimastat

    SP-8203

    MMP iGluR Neurological Disease
    Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury.
  • HY-30008
    Cycloleucine

    iGluR Cancer Infection Metabolic Disease Neurological Disease
    Cycloleucine is a specific inhibitor of S-adenosyl-methionine mediated methylation. Cycloleucine is antagonist of NMDA receptor associated glycine receptor, with a Ki of 600 μM. Cycloleucine is also a competitive inhibitor of ATP: L-methionine-S-adenosyl transferase in vitro. Cycloleucine has anxiolytic and cytostatic effects.
  • HY-12882A
    Ifenprodil tartrate

    iGluR Potassium Channel Neurological Disease
    Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM). Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator.
  • HY-139048A
    Fluoroethylnormemantine hydrochloride

    iGluR Neurological Disease
    Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects.
  • HY-139048
    Fluoroethylnormemantine

    iGluR Neurological Disease
    Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects.
  • HY-N0076
    Bilobalide

    (-)-Bilobalide

    Apoptosis Autophagy Endogenous Metabolite Neurological Disease
    Bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba, inhibits the NMDA-induced efflux of choline with an IC50 value of 2.3 µM. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Exerts protective and trophic effects on neurons.
  • HY-100839
    (RS)-(Tetrazol-5-yl)glycine

    D,L-(tetrazol-5-yl)glycine; LY 285265

    iGluR Neurological Disease
    (RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist. (RS)-(Tetrazol-5-yl)glycine has EC50s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively. (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice.
  • HY-100822
    (R)-(+)-HA-966

    (+)-HA-966

    iGluR Neurological Disease
    (R)-(+)-HA-966 ((+)-HA-966) is a partial agonist/antagonist of glycine site of the N-methyl-D-aspartate (NMDA) receptor complex. (R)-(+)-HA-966 selectively blocks the activation of the mesolimbic dopamine system by amphetamine. (R)-(+)-HA-966 can cross the blood-brain barrier and has the potential for neuropathic and acute pain.
  • HY-101809
    CNS-5161 hydrochloride

    CNS 5161A

    iGluR Cardiovascular Disease
    CNS-5161 hydrochloride is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
  • HY-42068
    (-)-Aspartic acid

    (R)-Aspartic acid; D-(-)-Aspartic acid

    Endogenous Metabolite iGluR Neurological Disease
    (-)-Aspartic acid is an endogenous NMDA receptor agonist.
  • HY-15069A
    Fanapanel hydrate

    ZK200775 hydrate; MPQX hydrate

    iGluR Neurological Disease
    Fanapanel hydrate (ZK200775 hydrate) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
  • HY-15069
    Fanapanel

    ZK200775; MPQX

    iGluR Neurological Disease
    Fanapanel (ZK200775) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
  • HY-15067
    DNQX

    FG 9041

    iGluR Cancer
    DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively).
  • HY-B1283
    Mephenesin

    iGluR Neurological Disease
    Mephenesin is an NMDA receptor antagonist, is a centrally acting muscle relaxant.
  • HY-100714A
    D-AP5

    D-APV; D-2-Amino-5-phosphonovaleric acid

    iGluR Neurological Disease
    D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors.
  • HY-103233
    DNQX disodium salt

    FG 9041 disodium salt

    iGluR Cancer
    DNQX (FG 9041) disodium salt, a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively).
  • HY-15085
    MDL 105519

    iGluR Neurological Disease
    MDL 105519 is a potent and selective antagonist of glycine binding to the NMDA receptor.
  • HY-101600
    RPR104632

    iGluR Neurological Disease
    RPR104632 is a specific antagonist of NMDA receptor, with potent neuroprotective properties.
  • HY-13457
    TCN 201

    iGluR Neurological Disease
    TCN 201 is a potent, selective and non-competitive antagonist of GluN1/GluN2A NMDA receptor, with a pIC50 of 6.8. TCN 201 is selective for GluN1/GluN2A NMDA receptor over GluN1/GluN2B NMDA receptor (pIC50<4.3).
  • HY-19243
    GV-196771A

    iGluR Neurological Disease
    GV-196771A is the sodium salt form of GV196771, is an NMDA receptor antagonist.
  • HY-12294
    PEAQX

    NVP-AAM077

    iGluR Neurological Disease
    PEAQX(NVP-AAM 077) is a potent and orally active NMDA antagonist with a 15-fold preference for human NMDA receptors with the 1A/2A(IC50=270 nM), rather than 1A/2B(29,600 nM).
  • HY-B1487
    Procyclidine hydrochloride

    (±)-Procyclidine hydrochlorid

    iGluR Neurological Disease
    Procyclidine hydrochloride is a potent anti-cholinergic agent, and is also known to have NMDA antagonist properties.
  • HY-15084B
    Dizocilpine

    MK-801

    iGluR Neurological Disease
    Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive NMDA receptor antagonist, with a Kd of 37.2 nM in rat brain membranes. Dizocilpine acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca 2+ flux.
  • HY-101037
    Sarcosine

    N-Methylglycine; Sarcosin

    Endogenous Metabolite GlyT Cancer
    Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia.
  • HY-16502
    Transcrocetinate disodium

    Disodium trans-crocetinate

    iGluR Cancer
    Transcrocetinate disodium, extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity.
  • HY-19391
    UK-240455

    iGluR Neurological Disease
    UK-240455 is a potent and selective N-methyl D-aspartate (NMDA) glycine site antagonist.
  • HY-42937
    Transcrocetin meglumine salt

    trans-Crocetin meglumine salt

    iGluR Cancer
    Transcrocetin meglumine salt, extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity.
  • HY-B0369A
    Orphenadrine citrate

    iGluR Neurological Disease
    Orphenadrine citrate is a NMDA receptor antagonist with Ki of 6.0 +/- 0.7 μM, HERG potassium channel blocker.
  • HY-17001A
    Flupirtine

    D 9998

    Potassium Channel iGluR Neurological Disease
    Flupirtine(D 9998) is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties.
  • HY-101620
    MRZ 2-514

    iGluR Neurological Disease
    MRZ 2-514 is an antagonist of the strychnine-insensitive modulatory site of the NMDA receptor (glycineB), with Ki of 33 μM.
  • HY-W018061
    Traxoprodil

    iGluR Neurological Disease
    Traxoprodil (CP101,606) is a potent and selective NMDA antagonist and protect hippocampal neurons with an IC50 of 10 nM.
  • HY-13059B
    SDZ 220-581 hydrochloride

    iGluR Neurological Disease
    SDZ 220-581 hydrochloride is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7.
  • HY-13059
    SDZ 220-581

    iGluR Neurological Disease
    SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7.
  • HY-B1126
    Orphenadrine hydrochloride

    iGluR Neurological Disease
    Orphenadrine hydrochloride is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 6.0 ±0.7 μM.
  • HY-100456
    ZL006

    iGluR Neurological Disease
    ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.
  • HY-18699
    CIQ

    iGluR Neurological Disease
    CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
  • HY-108235C
    (R)-Lanicemine

    (R)-AZD6765

    iGluR Neurological Disease
    (R)-Lanicemine ((R)-AZD6765) is the less active R-enantiomer of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects.
  • HY-102053
    Apimostinel

    NRX-1074; AGN-241660

    iGluR Neurological Disease
    Apimostinel (NRX-1074; AGN-241660) is an orally active NMDA receptor partial agonist.
  • HY-18698
    L-701324

    iGluR Neurological Disease
    L-701324 is an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor.
  • HY-13059A
    SDZ 220-581 Ammonium salt

    iGluR Neurological Disease
    SDZ 220-581 Ammonium salt is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7.
  • HY-13993A
    Ro 25-6981 Maleate

    iGluR Neurological Disease
    Ro 25-6981 Maleate is a potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit.
  • HY-15084
    Dizocilpine maleate

    MK-801 maleate

    iGluR Neurological Disease
    Dizocilpine maleate (MK-801 maleate) is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.
  • HY-B2121
    6-Methoxy-2-naphthoic acid

    Naproxen impurity O

    iGluR Neurological Disease
    6-Methoxy-2-naphthoic acid is an NMDA receptor modulator extracted from patent WO 2012019106 A2.
  • HY-N2311
    Ibotenic acid

    (RS)-Ibotenic acid; DL-Ibotenic acid

    iGluR Neurological Disease
    Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Qm) receptor sites.
  • HY-B0184A
    Felbamate hydrate

    W-554 hydrate; ADD-03055 hydrate

    iGluR Neurological Disease
    Felbamate hydrate (W-554 hydrate) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .
  • HY-B0184
    Felbamate

    W-554; ADD-03055

    iGluR Neurological Disease
    Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
  • HY-16312
    MDL-29951

    iGluR Neurological Disease
    MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with Ki of 0.14 μM for [ 3H]glycine binding in vitro and in vivo.
  • HY-16728B
    Rapastinel Trifluoroacetate

    GLYX-13 Trifluoroacetate

    iGluR Neurological Disease
    Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) is an NMDA receptor modulator with glycine-site partial agonist properties. Rapastinel Trifluoroacetate has the potential for major depressive disorder treatment.
  • HY-Y0966
    Glycine

    Endogenous Metabolite iGluR Neurological Disease
    Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
  • HY-N2370
    24-Hydroxycholesterol

    iGluR LXR Neurological Disease
    24-Hydroxycholesterol is a natural sterol, which serves as a positive allosteric modulator of N-Methyl-d-Aspartate (NMDA) receptorsR, and a potent activator of the transcription factors LXR.
  • HY-15068
    NBQX

    FG9202

    iGluR Neurological Disease
    NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity.
  • HY-12347
    Ro 61-8048

    Others Neurological Disease
    Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC50 of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations.
  • HY-15068A
    NBQX disodium

    FG9202 disodium

    iGluR Neurological Disease
    NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity.
  • HY-12294A
    PEAQX tetrasodium hydrate

    NVP-AAM077 tetrasodium hydrate

    iGluR Apoptosis Neurological Disease
    PEAQX (NVP-AAM077) tetrasodium hydrate is a potent, selective and orally active NMDA antagonist, with IC50 values of 270 nM and 29600 nM for hNMDAR 1A and hNMDAR 2A, respectively.
  • HY-106968
    ZD-9379

    iGluR Neurological Disease
    ZD-9379 is a potent, orally active, and brain penetrant full antagonist at the glycine site of the NMDA receptor. ZD-9379 has neuroprotective effect.
  • HY-107702
    CGP 37849

    iGluR Neurological Disease
    CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects.
  • HY-B1270
    Isoxsuprine hydrochloride

    Adrenergic Receptor iGluR Neurological Disease Endocrinology
    Isoxsuprine hydrochloride is a beta-adrenergic receptor agonist with Kis of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor antagonist.
  • HY-14777
    Radiprodil

    RGH-896

    iGluR Neurological Disease
    Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions.
  • HY-14608
    L-Glutamic acid

    Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
  • HY-107498
    GNE-8324

    iGluR Neurological Disease
    GNE-8324 is a selective GluN2A positive allosteric modulator. GNE-8324 selectively enhances NMDA receptor (NMDAR)-mediated synaptic responses in inhibitory but not excitatory neurons.
  • HY-100806
    Kynurenic acid

    Quinurenic acid

    iGluR Endogenous Metabolite Apoptosis Inflammation/Immunology Neurological Disease Endocrinology
    Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
  • HY-107512
    Kynurenic acid sodium

    iGluR Apoptosis Inflammation/Immunology Neurological Disease Endocrinology
    Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.
  • HY-W017500
    N-Methyl-DL-aspartic acid

    iGluR Neurological Disease
    N-Methyl-DL-aspartic acid is a glutamate analogue and acts as a potent neuronal excitant. N-Methyl-DL-aspartic acid is NMDA receptor agonist and can be used for neurological diseases research.
  • HY-P1594
    Dynorphin A (1-10)

    Opioid Receptor iGluR Neurological Disease
    Dynorphin A (1-10) an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) also blocks NMDA-activated current with an IC50 of 42.0 μM.
  • HY-14608A
    L-Glutamic acid monosodium salt

    Monosodium glutamate

    iGluR Apoptosis Ferroptosis Neurological Disease
    L-Glutamic acid monosodium salt acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). (S)-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
  • HY-106441A
    Rislenemdaz

    MK-0657; CERC-301

    iGluR Neurological Disease
    Rislenemdaz (CERC-301) is an orally bioavailable and selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM, respectively.
  • HY-B1176
    Equilin

    7-Dehydroestrone

    Estrogen Receptor/ERR Endocrinology
    Equilin (7-Dehydroestrone) is an important member of the large group of oestrogenic substances and is chemically related to menformon (oestrone). Equilin increases the growth of cortical neurons via an NMDA receptor-dependent mechanism.
  • HY-19168
    Perzinfotel

    EAA-090

    iGluR Neurological Disease
    Perzinfotel (EAA-090) is a potent, selective, and competitive NMDA receptor antagonist with neuroprotective effects. Perzinfotel (EAA-090) shows high affinity (IC50=30 nM) for the glutamate site.
  • HY-I0096
    Indole-2-carboxylic acid

    Endogenous Metabolite iGluR Neurological Disease
    Indole-2-carboxylic acid is a strong inhibitor of lipid peroxidation. Indole-2-carboxylic acid (I2CA) specifically and competitively inhibits the potentiation by glycine of NMDA-gated current.
  • HY-P1594A
    Dynorphin A (1-10) (TFA)

    Opioid Receptor iGluR Neurological Disease
    Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) (TFA) also blocks NMDA-activated current with an IC50 of 42.0 μM.
  • HY-100807
    Quinolinic acid

    Endogenous Metabolite iGluR Inflammation/Immunology Neurological Disease
    Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction.
  • HY-15071
    YM90K

    iGluR Neurological Disease
    YM90K is a potent and selective AMPA receptor antagonist with a Ki of 84 nM. YM90K is less potent in inhibiting kainate (Ki of 2.2 μM) and NMDA (Ki of 37 μM) receptors. YM90K has neuroprotective actions.
  • HY-N2072
    Transcrocetin

    trans-Crocetin

    iGluR Endogenous Metabolite Cancer
    Transcrocetin (trans-Crocetin), extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity. Transcrocetin (trans-Crocetin) is capable of crossing the blood-brain barrier and reach the central nervous system (CNS).
  • HY-B0184S
    Felbamate-d4

    iGluR Neurological Disease
    Felbamate-d4 (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
  • HY-12881
    Eliprodil

    SL-820715

    iGluR Neurological Disease
    Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM).
  • HY-101310
    SYM 2081

    iGluR Neurological Disease
    SYM 2081 is a high-affinity ligand and potent, selective agonist of kainate receptors, inhibits [ 3H]-kainate binding with an IC50 of 35 nM, almost 3000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively.
  • HY-15066
    CNQX

    FG9065

    iGluR Neurological Disease
    CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist. CNQX blocks the expression of fear-potentiated startle in rats.
  • HY-N0368
    Linalool

    iGluR Apoptosis Endogenous Metabolite Cancer Cardiovascular Disease
    Linalool is natural monoterpene in essential olis of coriander, acts as a competitive antagonist of Nmethyl d-aspartate (NMDA) receptor, with anti-tumor, anti-cardiotoxicity activity.Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome.
  • HY-101043
    4-PPBP maleate

    Sigma Receptor iGluR Neurological Disease
    4-PPBP maleate is a potent σ 1 receptor ligand and agonist. 4-PPBP maleate is a non-competitive, selective NR1a/2B NMDA receptors (expressed in Xenopus oocytes) antagonist. 4-PPBP maleate provides neuroprotection.
  • HY-107701
    CGP 78608 hydrochloride

    iGluR Neurological Disease
    CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity.
  • HY-109123
    Soticlestat

    TAK-935; OV935

    Cytochrome P450 Neurological Disease
    Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor. Soticlestat has the potential for epilepsy syndromes research.
  • HY-P2307
    Tat-NR2Baa

    iGluR NO Synthase Neurological Disease
    Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95.
  • HY-P2307A
    Tat-NR2Baa TFA

    iGluR NO Synthase Neurological Disease
    Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95.
  • HY-15703
    QNZ46

    iGluR Neurological Disease
    QNZ46 is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively).
  • HY-15066A
    CNQX disodium

    FG9065 disodium

    iGluR Neurological Disease
    CNQX disodium (FG9065 disodium) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist. CNQX disodium blocks the expression of fear-potentiated startle in rats.
  • HY-100808
    D-Serine

    (R)-Serine

    iGluR Endogenous Metabolite Others
    D-Serine ((R)-Serine), an endogenous amino acid involved in glia-synapse interactions that has unique neurotransmitter characteristics, is a potent co-agonist at the NMDA glutamate receptor. D-Serinee has a cardinal modulatory role in major NMDAR-dependent processes including NMDAR-mediated neurotransmission, neurotoxicity, synaptic plasticity, and cell migration.
  • HY-13993
    Ro 25-6981

    iGluR Neurological Disease
    Ro 25-6981 is a potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit. IC50 values are 0.009 and 52 μM for cloned receptor subunit combinations NR1C/NR2B and NR1C/NR2A respectively.
  • HY-14602
    Tramiprosate

    Homotaurine; 3-Amino-1-propanesulfonic acid

    Amyloid-β Cancer
    Tramiprosate (Homotaurine), an orally active and brain-penetrant natural amino acid found in various species of red marine algae. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog and possess neuroprotection, anticonvulsion and antihypertension effects.
  • HY-G0021
    N-Desmethylclozapine

    Norclozapine; Desmethylclozapine; Normethylclozapine

    mAChR Opioid Receptor Drug Metabolite Virus Protease Infection
    N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic drug Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist.
  • HY-17387
    (-)-Huperzine A

    Huperzine A

    AChE Apoptosis iGluR Neurological Disease
    (-)-Huperzine A (Huperzine A) is an alkaloid isolated from a Chinese club moss, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC50 of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease.
  • HY-100811
    7-Chlorokynurenic acid

    7-CKA

    iGluR Neurological Disease
    7-Chlorokynurenic acid (7-CKA) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid has potent antinociceptive actions after neuraxial delivery.
  • HY-103234A
    GYKI 52466 dihydrochloride

    iGluR Neurological Disease
    GYKI 52466 dihydrochloride is a potent, selective, orally active and non-competitive kainate- and AMPA-activated currents antagonist with IC50s of 7.5 μM and 11 μM, respectively. GYKI 52466 dihydrochloride is inactive against N-methyl-D-aspartate (NMDA) or γ-aminobutyric acid responses. GYKI 52466 dihydrochloride ia a muscle relaxant and anticonvulsant agent, and has good blood brain barrier permeability.
  • HY-100811A
    7-Chlorokynurenic acid sodium salt

    7-CKA sodium salt

    iGluR Neurological Disease
    7-Chlorokynurenic acid sodium salt (7-CKA sodium salt) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid sodium salt is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid sodium salt has potent antinociceptive actions after neuraxial delivery.
  • HY-116330A
    Hyperforin dicyclohexylammonium salt

    Hyperforin DCHA

    TRP Channel Calcium Channel Neurological Disease
    Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt shows antidepressant effect.
  • HY-N0215
    L-Phenylalanine

    (S)-2-Amino-3-phenylpropionic acid

    Calcium Channel iGluR Endogenous Metabolite Metabolic Disease
    L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca + channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals.
  • HY-100781
    D-AP4

    D-APB; D-2-Amino-4-phosphonobutyric acid

    iGluR Neurological Disease
    D-AP4 (D-APB; D-2-Amino-4-phosphonobutyric acid), a phosphono analogue of glutamate, is an NMDA broad spectrum excitatory amino acid receptor antagonist. D-AP4 also is an agonist for a quisqualate-sensitized AP6 site in hippocampus. D-AP4 inhibits AMPA receptor-stimulated 57Co 2+ influx in cultured cerebellar granule cells (IC50 ≥ 100 μM).
  • HY-100406
    (S)-MCPG

    (+)-MCPG

    mGluR Neurological Disease
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371). (S)-MCPG can be used for the study of the function of mGluRs in spatial learning.